source
- BioNTech's head and neck cancer vaccine fails to meet first primary endpoint in pivotal trialBioNTech reported that its experimental mRNA vaccine targeting head and neck cancer did not achieve one of the two primary goals in a pivotal study. The trial was designed to evaluate the vaccine’…
- Readily secures $11 million to expand AI compliance platform for insurersReadily, a San Francisco‑based startup, uses artificial intelligence to monitor and flag changes in government regulations that affect insurance companies. The company announced it has closed an $…